CGRP Education & Research Forum
Already a member? Become a member Register
youtubeLinkedIn
News
IHC 2019

Join us now

The Calcitonin Gene-Related Peptide (CGRP) Forum has been established by an international group of clinicians and researchers. It provides all healthcare professionals with open and free access to independent news, information, comment and resources about the exciting potential of CGRP as a novel therapeutic target for the prevention of migraine in millions of people worldwide.

View invitations from the editors
Become a member of CGRP Forum now

CGRP therapies in acute migraine

As clinicians await the US approval of the first CGRP small molecule receptor antagonist, ubrogepant, for the acute treatment of migraine, Peter Goadsby looks at the potential impact of targeting the CGRP pathway for both prevention and treatment of migraine.

Become a member-->

Why is CGRP an important therapeutic target?

Multiple lines of evidence support a role for CGRP in migraine pathophysiology.

Its blockade is now a potentially important therapeutic target for migraine prevention.

Read more Become a member

Is anti-CGRP therapy approved for your patients?

Take a look at our new expert guide to the regulatory status and approved indications for anti-CGRP therapies worldwide.

Read More
From the Editors
Our distinguished Editors discuss the latest developments and provide their views:Will CGRP antibodies put an end to migraine?View all articles
Members get free, open access - Register now »
Trials
Easy-to-access digests of all the key trials completed & ongoing:Eptinezumab (ALD403)Erenumab (AMG 334)Galcanezumab (LY2951742)Fremanezumab (TEV-48125)View all Trials